{"preliminary_commentary":{"by_channel":{"x_thread":38,"podcast":4,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06612151\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TAISHAN-302","nct_id":"NCT06612151","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=taishan-302-nct06612151. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants are randomized to receive YL201 monotherapy intravenously on Day 1 of each 3-week cycle at RP3D dose level, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent as specified in the protocol.","label":"YL201","type":"EXPERIMENTAL"},{"description":"Participants are randomized to receive topotecan hydrochloride intravenously, on Days 1 to 5 of each 3-week cycle per prescribing information, until PD, unacceptable toxicity, or withdrawal of consent as specified in the protocol.","label":"topotecan hydrochloride for injection","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12-01","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":438,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"YL201","otherNames":[],"type":"DRUG"},{"name":"topotecan hydrochloride for injection","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","official_title":"A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects With Relapsed Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To compare the OS of YL201 versus topotecan hydrochloride in subjects with relapsed SCLC.","timeFrame":"Approximately within 36 months"}],"references":[{"citation":"Zhao Y, Liu H, Meng X, Liu Z, Yu Y, Zheng Y, Sun L, Yang R, Liu J, Zhao Y, Wu L, Yang L, Zhang Z, Li M, Zhang P, Zhang Y, Zhong H, Cui J, Huang Z, Yin Y, Li M, Tong F, Xue D, Lv D, Li X, Zhang X, Chin S, Cai J, Xue T, Huang Y, Zhao H, Zhang L; TAISHAN-302 Investigators. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. N Engl J Med. 2026 Sep 12. doi: 10.1056/NEJMoa2610229. Online ahead of print.","pmid":"42734213","type":"DERIVED"}],"start_date":{"date":"2024-12-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)","url":"https://clinicaltrials.gov/study/NCT06612151"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/taishan-302-nct06612151"}